These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 20010168)

  • 21. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Thalidomide treatment in multiple myeloma].
    Hattori Y
    Rinsho Ketsueki; 2003 May; 44(5):302-12. PubMed ID: 12822404
    [No Abstract]   [Full Text] [Related]  

  • 23. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel therapies in myeloma.
    Hayden PJ; Mitsiades CS; Anderson KC; Richardson PG
    Curr Opin Hematol; 2007 Nov; 14(6):609-15. PubMed ID: 17898564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of older patients with multiple myeloma.
    Gay F; Palumbo A
    Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.
    Dimopoulos MA; Kastritis E; Christoulas D; Migkou M; Gavriatopoulou M; Gkotzamanidou M; Iakovaki M; Matsouka C; Mparmparoussi D; Roussou M; Efstathiou E; Terpos E
    Leukemia; 2010 Oct; 24(10):1769-78. PubMed ID: 20739955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
    Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
    Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib.
    Möller J; Nicklasson L; Murthy A
    J Med Econ; 2011; 14(6):690-7. PubMed ID: 21892856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
    Lee SS; Suh C; Kim BS; Chung J; Joo YD; Ryoo HM; Do YR; Jin JY; Kang HJ; Lee GW; Lee MH; Shim H; Kim K; Yoon SS; Bang SM; Kim HY; Lee JJ; Park J; Lee DS; Lee JH;
    Ann Hematol; 2010 Sep; 89(9):905-12. PubMed ID: 20349060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
    Hornberger J; Rickert J; Dhawan R; Liwing J; Aschan J; Löthgren M
    Eur J Haematol; 2010 Dec; 85(6):484-91. PubMed ID: 20846301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
    Guglielmelli T; Bringhen S; Rrodhe S; Gay F; Cavallo F; Berruti A; Montefusco V; Piro E; Benevolo G; Petrucci MT; Caravita T; Offidani M; Corradini P; Boccadoro M; Saglio G; Palumbo A
    Eur J Cancer; 2011 Apr; 47(6):814-8. PubMed ID: 21334196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
    Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
    Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
    Vogl DT; Stadtmauer EA; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Facon T; Harousseau JL; Boral A; Neuwirth R; Anderson KC
    Br J Haematol; 2009 Nov; 147(4):531-4. PubMed ID: 19725827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frontline treatment of multiple myeloma in elderly patients.
    Moreau P; Hulin C; Facon T
    Blood Rev; 2008 Nov; 22(6):303-9. PubMed ID: 18550234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase 2 study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide for patients with relapsed/refractory multiple myeloma.
    Berenson JR; Yellin O; Kazamel T; Hilger JD; Chen CS; Cartmell A; Woliver T; Flam M; Bravin E; Nassir Y; Vescio R; Swift RA
    Leukemia; 2012 Jul; 26(7):1675-80. PubMed ID: 22354206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New treatment strategy of multiple myeloma for cure].
    Murakami H; Handa H
    Gan To Kagaku Ryoho; 2006 Apr; 33(4):417-23. PubMed ID: 16612147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
    Jagannath S; Barlogie B; Berenson JR; Siegel DS; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Esseltine DL; Anderson KC
    Br J Haematol; 2008 Nov; 143(4):537-40. PubMed ID: 18783399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lenalidomide in multiple myeloma.
    Thomas SK; Richards TA; Weber DM
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.